http://rdf.ncbi.nlm.nih.gov/pubchem/reference/9254113

Outgoing Links

Predicate Object
contentType Journal Article|Research Support, Non-U.S. Gov't
endingPage 1379
issn 1532-1827
0007-0920
issueIdentifier 8
pageRange 1366-1379
publicationName British Journal of Cancer
startingPage 1366
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_d29184df8844e34b460482b1b6dbad96
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_2f59178ef0130ce488e362a206df02b7
isSupportedBy http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_31ed2239b63aabaeb1b65671cb76bc4c
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_ac1ee88038ffa984f0f912fcfb480ff7
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_70859ee93834db34eb99ce9e6a1682b1
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_5ae4ab06e5eb495f61d2d1674a4f518c
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_a18a0cf70b881e509f28adbc22b6325f
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_f847c1d505dd7710f71aa2629670b477
bibliographicCitation Varey AHR, Rennel ES, Qiu Y, Bevan HS, Perrin RM, Raffy S, Dixon AR, Paraskeva C, Zaccheo O, Hassan AB, Harper SJ, Bates DO. VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. British Journal of Cancer. 2008 Mar 18;98(8):1366–79. doi: 10.1038/sj.bjc.6604308.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_909672b98399ee4119412ca3d7893223
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d829d481d49c3b300268903baebd7307
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_efcddd408819684938faa0cc1ebcbc99
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f7b8b701cbeb0f186075b60574c9f257
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_478e61ab67cbe9b0fde1cb8665e1909d
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_244759461dbea70c604cdd257e87f392
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f998fe9262a1c33ea6fc14d903c69da1
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_89465034ee57f4752523ecbf8644155e
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3e7209ea1bebbf8ccdb963e156e4a323
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fa38c08895b456b9e03b818401adf606
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_13f5a2876d081f9c98a1056f71dc6cd9
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b196eb5d44c8d28314c03c4a69f92647
date 2008-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://pubmed.ncbi.nlm.nih.gov/18349829
https://pubmed.ncbi.nlm.nih.gov/PMC2361696
https://doi.org/10.1038/sj.bjc.6604308
isPartOf https://portal.issn.org/resource/ISSN/1532-1827
https://portal.issn.org/resource/ISSN/0007-0920
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1765
language English
source https://www.crossref.org/
https://scigraph.springernature.com/
https://pubmed.ncbi.nlm.nih.gov/
title VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy
discusses http://id.nlm.nih.gov/mesh/M0356369
http://id.nlm.nih.gov/mesh/M0443627
http://id.nlm.nih.gov/mesh/M0001357
http://id.nlm.nih.gov/mesh/M0029740
http://id.nlm.nih.gov/mesh/M0556300
http://id.nlm.nih.gov/mesh/M0019167
http://id.nlm.nih.gov/mesh/M0328153
http://id.nlm.nih.gov/mesh/M0441463
hasSubjectTerm http://purl.org/au-research/vocabulary/anzsrc-for/2008/11
http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7156
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6799
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_714b3f52d8149c3277181d9513b93112
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9672
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7306
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6914

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129071090
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127952853
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128364298
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135985134
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129071275
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128684338
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129159660
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128865459
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129430288
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136058681
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129308074
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129184137
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128133749
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128334455
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136084913
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129888650
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129711275

Total number of triples: 76.